17,261 trials
Acne Inversa
Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 16- Minimum Risk (MR) [Full Analysis Set (FAS), Non-responder Imputation…
Astrocytoma
Primary: Progression Free Survival at 6 Months (PFS6) — 47 percentage of participants
Acne Vulgaris
Primary: Change From Baseline in Facial Inflammatory Lesion Counts at Week 12 — -6.8; -7.4; -9.6 lesions — p=0.3757
End Stage Renal Disease
Primary: Number of Subjects Cured — 62 Participants
Malignant Neoplasms of Digestive Organs · Colorectal Cancer · Colon Cancer
Primary: Immune-related Best Overall Response Rate. — 1 Participants
Cholangiocarcinoma · Liver and Intrahepatic Bile Duct Carcinoma · Stage III Gallbladder Cancer AJCC v7
Primary: Progression Free Survival of Ramucirumab in Advanced Biliary Cancers — 3.2 months
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor · Microsatellite Stable (MSS) Colon Cancer
Primary: Number of Participants Experiencing a Dose Limiting Toxicity — 0 Participants
Covid19
Primary: For Clinical Domain: Time-to-sustained-resolution — 26; NA days — p=0.07
Chronic Lymphocytic Leukemia
Primary: Phase 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations Due to Adverse Events (AEs) — 3; 6…
Smoldering Multiple Myeloma
Primary: 2 Year Progression Free Percent — 62.5 percentage of participants
Alzheimer Disease · Dementia of Alzheimer Type
Primary: Event-related Potential (ERP) P300 Latency at Baseline — 361.5; 382.3; 375.3 Milliseconds (ms)
HIV
Primary: Change in Arterial Target to Background Ratio of 18-Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Uptake — -0.28; 0.01 ratio — p=0.01
Acute Ischemic Stroke · Transient Ischemic Attack (TIA)
Primary: Percent of Participants With Model Based Assessment of Composite of New Ischemic Stroke During Treatment and New Covert Brain Infarction (FLAIR + DWI) Detected by MRI by…
Solid Tumor
Primary: Part A: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 0 Participants
Anal Cancer
Primary: Overall Response Rate — 11.1 probability